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Abstract 
Background 
Retinopathy is increasingly recognized in prediabetic populations, and may herald 
increased risk of metabolic worsening. The Early Diabetes Intervention Program (EDIP) 
evaluated worsening of glycemia in screen-detected Type 2 diabetes, following 
participants for up to 5 years. Here we have evaluated whether the presence of 
retinopathy at the time of detection of diabetes was associated with accelerated 
progression of glycemia. 
Methods 
We prospectively studied 194 participants from EDIP with available baseline retinal 
photographs. Retinopathy was determined at baseline using 7-field fundus photography 
and defined as an Early Treatment of Diabetic Retinopathy Study Scale grading score 
of ≥20.  
Results 
At baseline, 12% of participants had classical retinal lesions indicating retinopathy. In 
univariate Cox proportional hazard analysis, the presence of retinopathy at baseline 
was associated with a doubled risk of progression of fasting plasma glucose (HR 2.02; 
95% CI 1.05-3.89). The retinopathy effect was robust to individual adjustment for age 
and glucose, the most potent determinants of progression in EDIP. 
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Conclusion 
Retinopathy was associated with increased risk of progression of fasting plasma 
glucose among adults with screen-detected, early diabetes.  Early detection of 
retinopathy may help individualize more aggressive therapy to prevent progressive 
metabolic worsening in early diabetes. 
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Introduction 
Microvascular disease of the retina is a common complication of diabetes, and in 
populations with Type 1 and Type 2 diabetes the prevalence and progression of 
retinopathy are clearly related to hyperglycemia. Retinal microvascular lesions typical of 
diabetic eye disease are also detectable in people without diabetes (Klein, 1992; 
Leibowitz et al., 1980; Wong, Klein, Sharrett, et al., 2003; Yu, Mitchell, Berry, Li, & 
Wang, 1998), and in these populations the clinical significance of these retinal lesions is 
less clear (Wong, Klein, Klein, et al., 2001). While these lesions may not be related to 
glycemia (Diabetes Prevention Program Research Group, 2007) they have been found 
to be associated with older age and systemic hypertension (Klein, Klein, Moss, & Wang, 
1994; Sharp et al., 1995; Svardsudd, Wedel, Aurell, & Tibblin, 1978; Yu et al., 1998), 
suggesting association with cardiometabolic risk. Indeed, population-based studies 
have described associations between retinopathy and future cardiovascular events, 
including in non-diabetic populations (Cheung, Rogers, et al., 2007; Cheung, Wang, et 
al., 2007; Klein et al., 2000; Liew, Wong, Mitchell, Cheung, & Wang, 2009; Wong, Klein, 
Couper, et al., 2001; Wong, Klein, Nieto, et al., 2003; Wong et al., 2002; Wong, 
Rosamond, et al., 2005). Only a small number of prospective studies have evaluated 
whether retinopathy in non-diabetic individuals predicts subsequent risk of diabetes 
(Klein, Klein, Moss, & Wong, 2006; Wong, Mohamed, Klein, & Couper, 2006). In this 
context the presence of retinopathy may serve as a readily accessible marker of risk of 
progression and allow more aggressive treatments to be targeted to those at higher risk 
of metabolic progression. The data on this question are sparse. 
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The Early Diabetes Intervention Program (EDIP) was a 5-year prospective randomized 
controlled trial evaluating the effect of acarbose versus placebo on a background of 
diet/exercise recommendations to delay progression of fasting glucose in a population 
with screen-detected, early type 2 diabetes. In the current study, we examined the 
relationships of retinopathy at baseline to the 5-year progression of fasting plasma 
glucose. Parallel analyses were performed with measures of nephropathy and 
neuropathy. 
Research Design and Methods 
EDIP was carried out between 1998 and 2004 at Indiana University School of Medicine 
and Washington University School of Medicine. The eligibility criteria, study design, and 
methods have been reported elsewhere (Kirkman et al., 2006). Participants were 
recruited from a population at high risk of diabetes, consisting of men and women at 
least 25 years of age with obesity, a history of gestational diabetes, or a family history of 
diabetes. They were eligible for the study if they had fasting plasma glucose (FPG) 
measurement between 105 mg/dl (5.5 mmol/l) and 140 mg/dl (7.8 mmol/l), the 
diagnostic FPG cutoff for diabetes at time of study inception, plus a 2-h post load 
plasma glucose (75-g oral glucose tolerance test) measurement ≥200 mg/dl (11.1 
mmol/l). Major exclusion criteria included recent treatment for cancer, recent major 
atherosclerotic events, and chronic infectious diseases. Full details of study 
inclusion/exclusion criteria have been previously published (Kirkman et al., 2006). 
Eligible participants received either acarbose or an identical placebo based on a blinded 
randomization stratified by site. Acarbose was titrated up to the maximum dose of 100 
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mg three times a day with meals, or the maximum tolerated dose, with matched dose 
increments among placebo treated individuals. At initiation of randomized study 
treatment, all subjects received diabetic diet counseling by a registered dietician, and 
were provided with standard of care recommendations for exercise (Kirkman et al., 
2006).  This advice was reinforced at quarterly visits. 
At baseline, each participant completed a standardized medical history, physical 
examination, electrocardiogram, seven-field fundus photography of both eyes, oral 
glucose tolerance test, laboratory testing, and 24-h urine collection for measurement of 
creatinine and albumin concentrations. Participants were seen quarterly for 
measurement of fasting plasma glucose concentration. The primary outcome for EDIP 
was the time to transition of fasting plasma glucose >140 mg/dL (7.8 mmol/L), 
confirmed on a repeat measurement at the next quarterly visit. This event was termed 
‘progression of fasting glucose’, and provided a metric of worsening glycemia amenable 
to time-to-event analyses. Participants who met criteria for progression did not undergo 
any further study measurements. 
The study protocol was approved by the institutional review boards of both institutions, 
and each patient signed an informed consent form for screening and for the trial. 
Assessment of microvascular disease  
Retinal photographs were acquired using a standardized protocol. Seven standard 
photographic fields were taken in each eye, by experienced retinal photographers who 
underwent central training and certification by the reading center in Madison WI. A 30º 
Zeiss FF series fund camera with Kodachrome 25 Daylight film was used, as specified 
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by the reading center.  Printed slide mages were read at a central unit using 
standardized methodology, with readers blinded to all participant information. 
Retinopathy scores and presence or absence of retinopathy was defined according to a 
simplified version of the Wisconsin grading system (ETDRS score ≥20 in either eye 
defining the categorical presence of retinopathy). 
Nephropathy was evaluated using the 24 hour urinary albumin:creatinine ratio using a 
Cobas MIRA autoanalyzer (Roche, Nutley NJ). A ratio ≥30 mg/g/24hr was used to 
define the categorical presence of nephropathy (Kramer & Molitch, 2005).  All laboratory 
measures were performed at a central study lab at Indiana University. 
Neuropathy was evaluated using 10-g monofilament testing on both feet. This testing 
was performed by physicians, and graded by the number of touches successfully 
identified by participants out of a total 10 per foot, with the presence of neuropathy 
determined if fewer than 8 touches were detected on either foot (Feng, Schlosser, & 
Sumpio, 2009). 
Anthropomorphic and Laboratory measurements 
Weight and height were measured with participants wearing light clothing, and the body 
mass index (BMI) was calculated as weight divided by the square of the height (kg/m2). 
Blood pressure was measured twice on the right arm while sitting, using a calibrated 
mercury sphygmomanometer. The average of these measurements was used for 
analysis.  
Glucose concentrations were determined using a glucose oxidase method (YSI, Yellow 
Springs, OH). Insulin was measured using a radioimmune assay (Linco Research, St 
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Charles, MO). HbA1c was measured using an immunoturbidometric assay (Roche 
Diagnostics, Indianapolis, IN). Total and HDL cholesterol and triglycerides were 
measured using an enzymatic end-point assay (Roche Diagnostics). LDL cholesterol 
concentration was derived using the Friedewald calculation if the value for triglycerides 
was <400 mg/dl. Non-esterified fatty acids were measured using a colorimetric method 
(Wako Diagnostics, Richmond VA). Beta cell function was quantified as the 
Insulinogenic Index, (IGI:[ins(30)-ins(0)]/[gluc(30)-gluc(0)]). Insulin resistance was 
estimated using HOMA-IR and 1/(fasting insulin). Disposition Index was calculated as 
IGI multiplied by 1/(fasting insulin). Glucose and insulin area under the curve following 
the oral glucose challenge were calculated as the excursion above baseline, using the 
trapezoidal rule. 
Statistical Analysis 
Cox proportional hazards models were used to assess the effect of baseline retinopathy 
on progression of the fasting plasma glucose. We adjusted for relevant metabolic, 
demographic and anthropometric baseline variables and change in variables in 
multivariable model. Change was calculated as [Yr1 – Yr0], because this provided both 
the maximal on-study effect and largest available dataset. A threshold significance 
value for these univariate relationships of p ≤0.1 was applied to select variables for 
inclusion in the multivariable models. Multivariable models were first constructed using 
only baseline variables, and then incorporating baseline and change variables that met 
these criteria.  
All statistical analyses were performed with SAS statistical software 9.4 SAS institute 
Inc. Cary, NC. Statistical significance was pre-specified at p<0.05. 
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Results 
The initial enrolled cohort of the EDIP trial comprised 216 participants. 196 subjects 
underwent at least two consecutive quarterly visits after the baseline visit, sufficient for 
determination of the pre-specified study endpoint. Of these, 2 subjects did not have 
information on baseline retinopathy. Hence, our final sample consisted of 194 subjects 
to evaluate the prospective relationship of baseline retinopathy with progression of 
fasting plasma glucose. Due to censoring at the time of progression (6) and individuals 
lost to follow-up (42) in the first year, analyses incorporating change in baseline 
variables to year 1 of follow-up included 164 subjects. After the first year the study 
retention was much improved, with the majority of censoring coming from progression 
events. Median duration on study was 30 months. 
At the baseline evaluation 24/194 subjects with retinal photographs had retinopathy 
(12.4%). In this population, the mean (SD) ETDRS scores in right and left eye 
respectively were 18.9 (16.6) and 17.3 (7.2) respectively among those with retinopathy, 
and 10.0 (0.0) and 10.0 (0.07) respectively among those without retinopathy. The 
scores for the worst eye among those meeting criteria for retinopathy were 23.7 (14.6), 
and the distribution of pairs of scores for both eyes were 10/10 n=168; 20/10 n=22; 
20/20 n=2; and >20/20 n=2. These 194 subjects did not differ in key anthropomorphic or 
metabolic variables from the complete set of subjects included at initiation of the study 
(not shown). The prevalence of neuropathy among individuals who underwent baseline 
assessments, regardless of subsequently undergoing randomization, was 19/225 
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evaluable participants (8.4%), and of nephropathy was 10/221 evaluable participants 
(4.5%). In this population there was little overlap of individuals affected by these 
conditions: Of 199 individuals with evaluable data for all 3 domains, 51 had evidence of 
one microvascular disease, 3 had two such conditions and none had all three.  
Table 1 presents demographic, anthropomorphic and metabolic variables at baseline, 
according to the presence or absence of retinopathy at baseline. None of these 
variables differed by presence or absence of retinopathy at baseline. Subjects with 
neuropathy at baseline had higher weight (113.8 (23.2) vs 96.9 (15.6) kg, p= 0.005) 
compared to subjects without neuropathy. Subjects with nephropathy at baseline had 
higher systolic blood pressure (149.0 (17.3) vs 132.5 (17.4), p=0.01) compared to 
subjects without nephropathy. Notable in this set of analyses were the very low mean 
HbA1c (6.2%), and a lack of differences in age, fasting plasma glucose, or blood 
pressure by retinopathy status (Table 1) or neuropathy status (not shown).  
In univariate Cox analysis, the presence of retinopathy at baseline was associated with 
a doubling of risk of progression of fasting plasma glucose (HR 2.02; 95%CI 1.05-3.89, 
Table 2). We next performed multivariable Cox analyses, first adjusting the retinopathy 
effect for relevant variables one by one (Table 2 Stage 1 Models). In these models, 
baseline retinopathy remained significantly associated with progression of fasting 
glucose while individually adjusting for age (p=0.039), weight (p=0.026), fasting plasma 
glucose (p=0.030), post challenge glucose values (p=0.060, p=0.050, and p=0.034 for 
values at 30 min, 60 min, and 120 min respectively), systolic and diastolic blood 
pressure (p=0.038 and p=0.037 respectively), or HbA1C (p=0.031). Similar analyses 
were performed incorporating individual Year 1 – Year 0 change variables individually 
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with retinopathy status (Table 2, Stage 1 Models). Each of these change terms 
individually caused the retinopathy term to lose statistical significance, with adjusted 
hazard ratio point estimates ranging from 1.54 to 1.92.  
The next analyses used multivariable cox proportional hazards modeling incorporating 
all baseline variables that met criteria for inclusion (Stage 2 Model 1), and incorporating 
all qualifying baseline and change variables (Stage 2 Model 2).  In the analysis 
incorporating baseline variables, retinopathy status was no longer statistically 
significantly associated with progression of glucose, with the point estimate of the 
hazard ratio for this term reduced to 1.80. In this model, younger age (p=0.03) and 
higher fasting plasma glucose (p<0.0001) were the dominant predictors of progression 
of fasting glucose. 
The analysis incorporating baseline and change variables also removed the statistical 
significance for retinopathy status, in this instance with a more profound effect on the 
associated point estimate of the hazard ratio (Table 2 Stage 2 Model 2). In this analysis, 
higher 30 min post glucose challenge (p=0.0002), lower 60 min post glucose challenge 
(p=0.009), and increase in 30 min post glucose challenge change (p<0.0001) were the 
persisting significant determinants for progression of fasting glucose. In the 
multivariable analyses mutually adjusting for baseline variables, the estimated hazard 
ratio associated with baseline retinopathy was not strongly reduced, although this term 
did not retain significance. In contrast the multivariable modeling incorporating baseline 
and Year 1 change variables produced a materially reduced estimated hazard ratio for 
the retinopathy term. 
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Baseline neuropathy and nephropathy were not associated with progression of fasting 
glucose. The hazard ratio associated with the presence of neuropathy was 1.39 (95% 
CI 0.50-03.84), p=0.53. The hazard ratio associated with nephropathy was 0.98 (95% CI 
0.31 – 3.12), p=0.97. 
 
Discussion 
The EDIP population was selected by virtue of having screen-detected Type 2 diabetes, 
specifically exhibiting post-challenge hyperglycemia but with less overt dysregulation of 
fasting glucose. Mean baseline HbA1c in this group at study entry was 6.2%, reflecting 
the very early stage of diabetes in this screen-detected population. Despite this early 
diabetes condition, the population had a 12.4% prevalence of retinopathy, an 8.4% 
prevalence of neuropathy and 4.5% prevalence of nephropathy at baseline (Kirkman et 
al., 2006). Here we have shown that having retinopathy at baseline was significantly 
associated with an increased risk of progression of fasting glucose (p=0.035, hazard 
ratio [95% confidence interval] of 2.02 [1.05 – 3.89]). In contrast there was no 
association of nephropathy or neuropathy at baseline with risk of progression of fasting 
glucose. The association of retinopathy with progression of fasting glucose was robust 
to individual adjustments for age, baseline weight, fasting glucose and HbA1c, but lost 
its significance in multivariable models incorporating these baseline and change in 
factors at the end of first year. This suggests that an assessment of retinopathy could 
be of value in initial assessments of risk of metabolic worsening in early diabetes, 
adding information beyond the risk associated with age and glycemia. 
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An association of retinal disease with prospective risk of metabolic worsening is not 
widely known, although a small number of publications have evaluated these 
relationships. Retinal arteriolar narrowing has been proposed as a predictor for 
development of diabetes (Wong, Shankar, Klein, Klein, & Hubbard, 2005). Similarly, the 
Australian Diabetes, Obesity and Lifestyle (AusDiab) Study showed that narrower retinal 
arterioles were associated with increased risk of developing diabetes, independent of 
FPG and SBP (Nguyen et al., 2008). More traditional diabetes-related retinopathy (i.e. 
dot-blot hemorrhage, macular edema) has also been associated with risk of metabolic 
progression. In the ARIC (Atherosclerosis Risk In Communities) study, the presence of 
ETDRS-defined retinopathy was associated with subsequent risk for diabetes in 
individuals with a family history of diabetes (Wong et al., 2006). In the Blue Mountains 
Eye study, 3.5% developed diabetes over 5 years among 195 individuals having 
retinopathy lesions at baseline (Cugati et al., 2006). In the Beaver Dam Eye Study, 
retinopathy was present in 7.3% of non-diabetic persons and these people were more 
likely to subsequently develop diabetes over the next 15 years (OR 1.70, 95%CI 1.17-
2.48, p=0.005) (Klein et al., 2006). In a cross-sectional study by Chowdhury et al. 
retinopathy in newly diagnosed Type 2 diabetes (mean HbA1c) was associated with 
lower beta cell responsiveness, insulin resistance, and insulin levels, and elevated 
fasting and postprandial glucose (Roy Chowdhury et al., 2016). In our study we see an 
association of retinopathy with progression of fasting plasma glucose, but we found no 
association found between retinopathy and baseline levels of beta cell function, insulin 
resistance, and insulin levels. This difference in observed associations is presumably 
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due to the different underlying patient populations, with differing ranges of the variables 
being compared.  
Our observations extend and augment these prior reports. We confirm the prospective 
relationship of baseline retinopathy lesions with increased risk of progressive 
dysglycemia, within a group with early screen-detected diabetes. Further, we provide 
quantification of the strength of the relationship of retinopathy versus other factors that 
are predictive of glycemic progression. Our study used more rigorous ascertainment of 
glycemic progression than has been used in prior reports, and applied a research-
standard evaluation of retinopathy using readers blinded to participant characteristics. 
By virtue of the strength of our outcome assessments, many of the components of our 
multivariable analyses were more robustly ascertained than has been possible in the 
above population studies reporting this association.  
The mechanism(s) underlying the association of prevalent retinopathy with progressive 
metabolic worsening are unknown. It is possible that the presence of retinopathy may 
simply be informing us that the affected individual has experienced a greater magnitude 
or duration of exposure to elevated glucose levels than is evident in their current 
glucose values. Since glucose itself is a strongly dominant predictor of progressive 
dysglycemia in this dataset (Table 2) and others (Cameron et al., 2008; Sattar et al., 
2008; Wilson, D'Agostino, Parise, Sullivan, & Meigs, 2005; Wilson et al., 2007), the prior 
existence of important levels of dysglycemia would be a logical connection with 
retinopathy. A recent report found an inverse association of fasting measures of β-cell 
function with retinopathy prevalence (Kuo et al., 2014), consistent with this notion. 
However, in our population there was no difference in the insulinogenic index or the 
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disposition index at baseline by retinopathy status (Table 1), suggesting that impaired β-
cell function may be an insufficient explanation. It is also possible that the presence of 
retinopathy identifies an individual with an increased microvascular susceptibility to 
glycemia, such that even modest elevations promote disease progression. A third 
possibility is that the presence of retinopathy is due to some shared factor arising with 
the dysmetabolic state that is common to vascular and metabolic worsening (i.e. a 
‘common soil’). Our analyses do not distinguish among these three possibilities but it is 
worth noting that the observations in adjusted univariate analyses suggest that the 
effect of retinopathy on risk of progression may be independent of glucose. Further 
evidence for a glucose-independent relationship is the lack of parallel observations in 
our cohort in the association of nephropathy and neuropathy with progression of 
glucose, although factors such as detection sensitivity and glucose exposure thresholds 
for disease may be masking true underlying associations. Future studies will need to be 
designed to specifically to address these questions. 
Limitations  
The current evaluations are post-hoc analyses of data collected in the context of a 
clinical trial, and therefore must be viewed as hypothesis-generating. The randomized 
treatment did not affect the relationship between retinopathy and progression of fasting 
glucose, but nevertheless this dataset differs from more traditional epidemiologic 
evaluations of these prospective relationships. The methodologies used for detection 
and quantification of retinopathy and nephropathy were arguably more sensitive than 
the standard methods used to detect and quantify neuropathy. Nevertheless, the 
methods used for retinopathy and nephropathy were of high quality and all methods are 
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parallel to those used in clinical practice, helping ensure that these observations can be 
interpreted in the context of routine clinical observations. The reduced number of 
subjects with evaluable data for analyses incorporating Year 1 data is in part an artifact 
of the study design, where subjects who met the study endpoint were no longer 
followed. Despite this a large majority of the original enrollees had data evaluable for 
these analyses, and this subgroup was clearly representative of the baseline cohort. On 
this basis we conclude that these analyses are representative of individuals with similar 
degrees of dysglycemia. The notion of assessing retinopathy as a biomarker or risk 
factor for diabetes has some appeal in that it is relatively simple, non-invasive, and well 
tolerated. Nevertheless, such an effort would require including retinopathy 
assessments, with associated resource needs and costs, in the overall risk factor profile 
of individuals being assessed for risk of glycemic worsening. This may not be feasible or 
realistic in the general population with current methods, but could be of value in clinical 
trials of diabetes prevention or β-cell function preservation.  
 
 
Conclusions 
In this population with early, screen-detected type 2 diabetes, we found that the 
presence of retinopathy lesions at baseline was associated with a two-fold increased 
risk of progression of fasting plasma glucose. Other microvascular disease measures 
that including reduced monofilament sensation and elevated urinary albumin:creatinine 
ratio at baseline were not predictors of progression of fasting plasma glucose, although 
18 
the prevalence of these conditions was low in this population which presumably limited 
our power for demonstrating such relationships even if they truly existed.  Early 
detection of retinopathy may help individualize more aggressive therapy to prevent 
progressive metabolic worsening in early diabetes. 
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Figure 1. Time course of progression of fasting glucose by retinopathy status at 1 
baseline. The survival curve depicts time to censoring events and event-free survival 2 
among participants with and without retinopathy at baseline. The p value represents the 3 
effect of baseline retinopathy on event-free survival in a Cox proportional hazards 4 
model. The numbers of individuals remaining in each group at each annual time point 5 
across the 5 years of observation are presented in the box below the figure. 6 
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Figure 1 – Time course of progression of fasting glucose by retinopathy at baseline 92 
 93 
94 
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Table 1: Baseline characteristics of the EDIP population by retinopathy, neuropathy, and 95 
nephropathy status 96 
Baseline characteristics Retinopathy (n=194) 
 Yes (n=24) No (n=170) p-value 
 N (%) N (%)  
Treatment   0.41 
• Acarbose 10 (41.7) 86 (50.6)  
• Placebo 14 (58.3) 84 (49.4)  
Sex    0.59 
• Male 7 (29.2) 59 (34.7)  
• Female 17 (70.8) 111 (65.3)  
 Mean±SD Mean±SD  
Age (years) 54.6±11.6 54.1±11.5 0.85 
Weight (kg) 97.9±18.3 97.8±20.4 0.98 
BMI (kg/m2) 35.3±7.5 34.8±6.6 0.74 
FPG (mmol/min) 6.8±0.8 6.7±0.8 0.67 
OGTT 30 min glucose 
(mmol/L) 
10.8±2.2 10.9±1.9 0.89 
OGTT 60 min glucose 
(mmol/L) 
13.3±1.7 13.4±1.9 0.74 
OGTT 120 min glucose 
(mmol/L) 
12.7±1.62 13.1±1.7 0.27 
HbA1C (%) 6.3±0.7 6.0±1.8 0.22 
24 
Systolic BP (mmHg) 130.5±14.0 133.4±17.9 0.46 
Diastolic BP (mmHg) 75.7±12.2 75.3±11.0 0.87 
Lipids (mmol/L)    
• Total Cholesterol 5.0±1.1 5.0±1.0 0.96 
• HDL Cholesterol 1.0±0.3 1.0±0.2 0.40 
• LDL Cholesterol 3.1±1.0 3.0±0.9 0.80 
• Triglycerides 1.9±0.9 2.2±1.2 0.22 
HOMA-IR (U) 5.4±4.0 5.6±4.0 0.75 
Fasting Insulin (pmol/L) 127.9±84.5 138.3±85.9 0.59 
Insulinogenic Index 
(pmol/mmol) 
53.8±72.4 68.7±78.6 0.39 
Disposition Index (U) 0.4±0.4 0.6±0.4 0.25 
Fasting NEFA (mmol/L) 627.6±151.5 568.9±204.3 0.18 
 97 
Table 1 Note: P-values reported are from chi-square analysis for categorical variables, or unpaired t-test for 98 
continuous variables. Sample sizes in the column headings represent the number of evaluable participants for 99 
each microvascular complication. Abbreviations: BMI, body mass index; FPG, fasting plasma glucose; HTN, 100 
hypertension; BP, blood pressure; HDL, high density lipoprotein; LDL, low density lipoprotein; HbA1C, 101 
hemogloblin A1C; HOMA-IR, homeostasis model of insulin resistance; NEFA, non-esterified fatty acids; OGTT, 102 
oral glucose tolerance test.  103 
104 
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 105 
Table 2: Cox proportional hazards model evaluating effect of baseline retinopathy on 106 
progression of fasting glucose 107 
 FPG Progression 
 p-value Retinopathy HR (95% 
CI) 
N = 194 
Retinopathy (0=No, 1=Yes)  0.035 2.02 (1.05 – 3.89) 
N = 194 
Stage 1: Baseline variables  
Retinopathy + treatment group (acarbose vs. placebo) 0.046 1.96 (1.01 – 3.79) 
Retinopathy + Age (years) 0.039 1.99 (1.04 – 3.84) 
Retinopathy + Weight (kg) 0.026 2.12 (1.10 – 4.08) 
Retinopathy + FPG (mmol/L) 0.030 2.08 (1.08 – 4.01) 
Retinopathy + OGTT 30 min glucose (mmol/L) 0.060 1.88 (0.97 – 3.63) 
Retinopathy + OGTT 60 min glucose (mmol/L) 0.050 1.93 (1.01 – 3.72) 
Retinopathy + OGTT 120 min glucose (mmol/L) 0.034 2.04 (1.06-3.92) 
Retinopathy + Fasting NEFA (mmol/L) 0.11 1.73 (0.89 – 3.38) 
Retinopathy + HbA1c (%) 0.031 2.06 (1.07 – 3.98) 
26 
Retinopathy + SBP (mmHg) 0.038 2.01 (1.04-3.88) 
Retinopathy + DBP (mmHg) 0.037 2.02 (1.05-3.90) 
N = 164 
Stage 1: Change variables 
Retinopathy + Δ FPG (mmol/L) 0.16 1.67 (0.82- 3.42) 
Retinopathy + Δ OGTT Glucose (30 min – 0 min) (mmol/L) 0.08 1.92 (0.93 – 3.94) 
Retinopathy + Δ OGTT Glucose (60 min – 0 min) (mmol/L) 0.11 1.80 (0.88 – 3.69) 
Retinopathy + Δ OGTT AUC Excursion (mmol/L * min) 0.12 1.75 (0.86 – 3.59) 
Retinopathy + Δ Fasting Insulin (pmol/L) 0.27 1.55 (0.71 – 3.40) 
Retinopathy + Δ HbA1C (%) 0.26 1.54 (0.73 – 3.22) 
Retinopathy + Δ weight 0.13 1.74 (0.85-3.55) 
N = 194 
Stage 2 Model 1: Multivariable analysis with baseline variables HR (95%CI) per 
variable 
Retinopathy  0.12 1.80 (0.87 – 3.76) 
Treatment group (acarbose vs. placebo) 0.60 1.16 (0.67-2.03) 
Age  0.03  0.97 (0.94 – 1.00) 
Weight  0.12 1.01 (1.00 – 1.02) 
FPG  <0.0001 3.07 (1.81 – 5.20) 
27 
OGTT 30 min glucose  0.27  1.10 (0.93 – 1.31) 
OGTT 60 min glucose 0.36 0.91 (0.75-1.11) 
OGTT 120 min glucose  0.32 1.09 (0.92-1.30) 
HbA1c 0.42 1.28 (0.85 – 1.93) 
SBP  0.24 0.99 (0.97-1.01) 
DBP  0.76 1.04 (0.98-1.03) 
N = 164 
Stage 2 Model 2: Multivariable analysis with baseline and change variables 
Retinopathy  0.78 1.14 (0.45 – 2.90) 
Treatment group 0.96 0.98 (0.53-1.82) 
Age  0.14 0.98 (0.95 – 1.01) 
Weight   0.19 1.01 (0.99 – 1.03) 
FPG   0.10 1.67 (0.90 – 3.11) 
OGTT 30 min glucose   0.0002 1.55  (1.24-1.95) 
OGTT 60 min glucose 0.009 0.76 (0.61-0.93) 
OGTT 120 min glucose 0.24  1.01 (1.00-1.02) 
HbA1c   0.77 1.09 (0.61 – 1.94) 
SBP 0.057  0.98 (0.97-1.00) 
DBP 0.19 1.02 (0.99-1.05) 
28 
Δ OGTT Glucose (30 min – 0 min) (mmol/L) <0.0001 1.58 (1.34-1.87) 
 108 
Abbreviations: Δ, delta; AUC, area under the curve; FPG, fasting plasma glucose; HbA1C, 109 
hemogloblin A1C; NEFA, non-esterified fatty acids; OGTT, oral glucose tolerance test; SBP, 110 
systolic blood pressure; DBP, diastolic blood pressure; HR, hazard ratio; CI, confidence 111 
interval 112 
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